B.Riley Securities initiated coverage of Cardiol Therapeutics Inc. (NASDAQ: CRDL) with a Buy rating and a $11.00 price target, highlighting the clinical and commercial potential of CardiolRx, an oral therapy candidate for recurrent pericarditis.
The firm’s bullish stance follows a 110% year-to-date gain that has brought CRDL to $2.00, near its 52-week high of $2.02. B.Riley’s target implies roughly 450% upside from current levels, underscoring confidence in CardiolRx’s development path and market opportunity.
CardiolRx is positioned as a potential first oral maintenance therapy for recurrent pericarditis, a relapsing inflammatory condition of the pericardium. The drug candidate holds orphan drug designation and targets the interleukin-1 pathway at the transcriptional level, aiming to control IL-1 release. Its mechanism contrasts with the currently approved rilonacept (ARCALYST), which requires weekly subcutaneous injections and generated $980 million to $995 million in fiscal 2026 guidance.
Top-line data from the Phase 3 MAVERIC trial is anticipated in the first quarter of 2027, a milestone that could validate CardiolRx’s efficacy and support regulatory and commercial planning. B.Riley estimates the U.S. recurrent pericarditis market includes approximately 37,000 patients, with an initial target of around 14,000 patients experiencing two or more recurrences. The drug has already reached more than 4,550 prescribers.
ARCALYST, licensed by Kiniksa from Regeneron in 2017 and FDA-approved in March 2021, commands an annual cost near $302,000, reflecting the high unmet need in this indication. The competitive landscape has drawn interest from major players, including Eli Lilly’s $1.2 billion acquisition of Ventyx in January 2026, which analysts view as validation of the therapeutic class.
Cardiol Therapeutics’ balance sheet remains strong, with a current ratio of 5.55 and more cash than debt. InvestingPro data shows analyst price targets for CRDL ranging from $4.95 to $10.01, with a consensus rating of Strong Buy.
